Common Contracts

Shared Care Guideline

Shared Care Guideline • March 28th, 2021

• Contract Type
  Shared Care Guideline
• Filed
  March 28th, 2021

Patiromer use in Adults Introduction This shared care agreement outlines the responsibilities between the specialist and the generalist for managing the prescribing of patiromer. Indication Hyperkalaemia in patients with heart failure or stage 3b to 5 chronic renal failure if they have1. Patients with persistent hyperkalaemia with a confirmed serum potassium level of at least 6.0 mmol/L, and2. Are not taking, or are taking a reduced dosage of, a renin- angiotensin-aldosterone system (RAAS) inhibitor because of hyperkalaemia, and3. Are not on dialysis Use in line with NICE TA623 – patiromer for treating hyperkalaemia (February 202) https://www.nice.org.uk/guidance/ta623 Dosage and administration Initially 8.4g OD; adjusted in steps of 8.4g as required, dose adjustments should be made at intervals of at least one week; maximum 25.2g per day. Formulations: 8.4g and 16.8g sachets Contraindications and cautions Contra-indications: Hypersensitivity to the active substance or to any excip